Pancreatic Exocrine Secretion and Weight Gain After Pancreas Transplantation.

clinical outcomes descriptive diabetes endocrinology general growth and development posttransplant statistics type 2

Journal

Progress in transplantation (Aliso Viejo, Calif.)
ISSN: 2164-6708
Titre abrégé: Prog Transplant
Pays: United States
ID NLM: 100909380

Informations de publication

Date de publication:
09 2023
Historique:
medline: 28 8 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Weight gain after pancreas transplant is a poorly understood phenomenon thought to be related to increased posttransplant insulin production, immunosuppressive medications, and appetite changes. No study has investigated the effect of increased exocrine secretion posttransplant. We hypothesized that exocrine function, measured by fecal elastase-1 (FE-1), was normal posttransplant and not correlated with weight gain. Our primary aim was to investigate changes in FE-1 levels with pancreas transplantation and to correlate this with weight gain. Establishing weight trends and identifying additional correlating factors were secondary aims. Forty-two patients that underwent simultaneous pancreas and kidney or pancreas after kidney transplant at a single center between 2013 and 2021 were included. Fecal elastase was measured prospectively in each patient at a single time point, with >500 µg/g categorized as high. Weight and C-peptide values were obtained. All the patients were on steroid-free immunosuppression. Nineteen patients (45%) had fecal elastase levels >500 µg/g, with a maximum of 3910 µg/g; 43% had levels greater than twice the upper limit of normal. The biggest increase in weight occurred between years 1 and 2, which continued to a median weight gain of 14% at 3 years. There was no correlation between weight gain and FE-1, pretransplant C-peptide levels, or duration of diabetes. This study demonstrated supranormal fecal elastase levels and weight gain posttransplant; however, there was no correlation. Future study with serial FE-1 before and after transplant is needed to better assess its correlation with weight gain.

Identifiants

pubmed: 37518975
doi: 10.1177/15269248231189877
doi:

Substances chimiques

C-Peptide 0
Pancreatic Elastase EC 3.4.21.36

Banques de données

ClinicalTrials.gov
['NCT04690738']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

236-241

Auteurs

Amanda Van Jacobs (A)

Department of Surgery, University Transplant Program, Rush University Medical Center, Chicago, IL, USA.

Michael D Williams (MD)

Department of Surgery, University Transplant Program, Rush University Medical Center, Chicago, IL, USA.

Oliver G Ralph (OG)

Department of Surgery, University Transplant Program, Rush University Medical Center, Chicago, IL, USA.

Adan Z Becerra (AZ)

Department of Surgery, University Transplant Program, Rush University Medical Center, Chicago, IL, USA.

Edie Y Chan (EY)

Department of Surgery, University Transplant Program, Rush University Medical Center, Chicago, IL, USA.

Oyedolamu Olaitan (O)

Department of Surgery, University Transplant Program, Rush University Medical Center, Chicago, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH